Tuesday, December 14, 2021 12:26:07 PM
Pfizer jabs protect 70% against hospitalization from omicron
A large-scale analysis in South Africa says that two-dose Pfizer/BioNTech vaccination provides just 33% protection against infection by the omicron coronavirus variant but 70% protection against hospitalization
By ANDREW MELDRUM Associated Press
December 14, 2021, 6:01 AM ET
• 4 min read
CDC panel to weigh in on Pfizer's COVID-19 vaccine for younger kidsAn independent CDC advisory panel will vote Tuesday on whether to recommend Pfizer's COVID-19 vaccine for children ages 5 to 11 in the U.S.The Associated Press
JOHANNESBURG -- A two-dose Pfizer/BioNTech vaccination provides just 33% protection against infection by the omicron variant of the coronavirus, but 70% protection against hospitalization, according to a large-scale analysis in South Africa released Tuesday.
The first large-scale analysis of vaccine effectiveness in the region where the new variant was discovered appears to support early indications that omicron is more easily transmissible and that the Pfizer shot isn't as effective in protecting against infection as it was against the delta variant.
The analysis was based on more than 211,000 positive COVID-19 test results, 41% from adults who had received two doses of the Pfizer vaccine. About 78,000 of these positive COVID-19 test results between Nov. 15 and Dec. 7 were attributed to omicron infections. The study was carried out by Discovery Health, South Africa's largest private health insurer, and the South African Medical Research Council.
The study has been carried out in the weeks since omicron was first announced in November by scientists in South Africa and Botswana. The researchers emphasized that its findings are preliminary and not peer reviewed.
The data are gathered from the first three weeks of South Africa’s omicron-driven wave and may change as time passes. South Africa is the first country to experience a surge in COVID-19 driven by the omicron variant.
South Africa has experienced rapid community spread — concentrated in its most populous province, Gauteng — dominated by the omicron variant.
The seven-day rolling average of daily new cases in South Africa has risen over the past two weeks from 8.07 new cases per 100,000 people on Nov. 29 to 34.37 new cases per 100,000 people on Dec. 13, according to Johns Hopkins University. The death rate hasn't increased during that same period.
“Superb genetic surveillance by the Network for Genomic Surveillance in South Africa identified that omicron infection accounts for over 90% of new infections in South Africa, and has displaced the formerly dominant delta variant,” Discovery Health chief executive Dr. Ryan Noach said.
“The omicron-driven fourth wave has a significantly steeper trajectory of new infections relative to prior waves. National data show an exponential increase in both new infections and test positivity rates during the first three weeks of this wave, indicating a highly transmissible variant with rapid community spread of infection,” Noach said.
The result shows that vaccinated individuals who received two doses of the Pfizer vaccine have 33% protection against infection from omicron, relative to those who were unvaccinated in the first weeks of South Africa’s current omicron-driven wave. This represents a significant drop from the 80% protection against infection afforded during the earlier period, probably on the basis of lower antibody susceptibility, following the extensive spike protein mutations in the omicron variant.
Encouragingly though, the result shows that these same vaccinated individuals who received two doses of the Pfizer vaccine have 70% protection against hospital admission in this same time period. This protection against hospital admission is reduced from the highs of 93% in South Africa’s delta-driven variant.
The study shows that the protection against hospital admission is maintained across all ages, in people from 18 to 79 years old, with slightly lower levels of protection for older people, with 67% in people age 60 to 69 and 60% for people age 70 to 79. Protection against admission is also consistent across a range of chronic illnesses including diabetes, hypertension, hypercholesterolemia, and other cardiovascular diseases.
———
The study also found:
1. Omicron poses a higher risk of reinfection. For individuals who have previously had COVID-19, the risk of reinfection with omicron is significantly higher than that of earlier variants.
2. Risk of hospitalization from omicron is lower. Hospital admissions among adults diagnosed with COVID-19 attributed to omicron is 29% lower compared to the COVID-19 wave that South Africa experienced in mid-2020, after adjusting for vaccination status.
BNTX $$$$
BNTX $$$$
DO always your own DD , before you invest in any stock !
My opinion is always only my opinion !
Good Luck to all !
Recent BNTX News
- Anglo American Rejects BHP Group’s Offer, Toyota Invests $1.4 Billion in Indiana, and More News • IH Market News • 04/26/2024 11:48:07 AM
- Coca-Cola and Microsoft Sign Billion-Dollar Agreement, Apple Event Set for May 7, and More News • IH Market News • 04/24/2024 11:28:02 AM
- BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024 • GlobeNewswire Inc. • 04/22/2024 10:45:00 AM
- Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer • GlobeNewswire Inc. • 04/07/2024 06:00:00 PM
- Apple Pre-Market Drop Due to Antitrust Threats, Surprising Profit Boosts Micron Shares, and Latest Market Updates • IH Market News • 03/21/2024 11:17:26 AM
- U.S. Index Futures Trade Sideways Amid Anticipation of Fed’s Policy Update; Oil Prices Dip • IH Market News • 03/20/2024 11:17:32 AM
- BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update • GlobeNewswire Inc. • 03/20/2024 10:15:00 AM
- BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer • GlobeNewswire Inc. • 03/20/2024 10:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/11/2024 01:04:00 PM
- BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024 • GlobeNewswire Inc. • 03/11/2024 11:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 12, 2024 in BioNTech Lawsuit - BNTX • PR Newswire (US) • 03/11/2024 10:25:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/07/2024 01:41:50 PM
- BioNTech Announces Planned Retirement of Sean Marett • GlobeNewswire Inc. • 03/07/2024 11:45:00 AM
- BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024 • GlobeNewswire Inc. • 03/06/2024 11:45:00 AM
- The Gross Law Firm Reminds BioNTech SE Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 12, 2024 - BNTX • PR Newswire (US) • 03/05/2024 10:45:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/28/2024 11:26:07 PM
- Shareholders that lost money on BioNTech SE(BNTX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 02/26/2024 10:45:00 AM
- BioNTech SE Sued for Securities Law Violations - Contact The Gross Law Firm Before March 12, 2024 to Discuss Your Rights - BNTX • PR Newswire (US) • 02/22/2024 10:45:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/15/2024 09:10:24 PM
- Shareholders that lost money on BioNTech SE(BNTX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 02/15/2024 10:00:00 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 12:26:25 PM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of BioNTech SE(BNTX) Shareholders • PR Newswire (US) • 02/09/2024 10:45:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/08/2024 11:08:22 AM
- BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs • GlobeNewswire Inc. • 02/08/2024 10:45:00 AM
- BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs • GlobeNewswire Inc. • 02/08/2024 10:45:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM